Title: Comparison of different second line treatments for metastatic pancreatic cancer: a
systematic review and network meta-analysis
Version: 5 Date: 14 May 2023
Reviewer:  Qiancheng Hu
Reviewer's report:
Recently, Citterio and co-workers have recently reviewed second line with oxaliplatin-
or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer (2018 Jul
3;9(51):29801-29809). First, I want to know why you did it again; in other words, what  do we
know and what do we not know? Second, exclusion criteria is not standardized, such as 'Also, we
excluded observational or phase I studies, reviews, letters, editorials, meeting abstracts, and case
reports'. Lastly,for any network meta-analysis, we would like to see more the quality evaluation
and data analysis of related  drug and non-drug interventions (2019; 367: l5460).
Title: Comparison of different second line treatments for metastatic pancreatic cancer: a
systematic review and network meta-analysis
Version: 5 Date: 14 May 2023
Reviewer:  Qiancheng Hu
Reviewer's report:
Recently, Citterio and co-workers have recently reviewed second line with oxaliplatin-
or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer (2018 Jul
3;9(51):29801-29809). First, I want to know why you did it again; in other words, what  do we
know and what do we not know? Second, exclusion criteria is not standardized, such as 'Also, we
excluded observational or phase I studies, reviews, letters, editorials, meeting abstracts, and case
reports'. Lastly,for any network meta-analysis, we would like to see more the quality evaluation
and data analysis of related  drug and non-drug interventions (2019; 367: l5460).
Please review this paper.
user
Title: Comparison of different second line treatments for metastatic pancreatic cancer: a
systematic review and network meta-analysis
Version: 5 Date: 14 May 2023
Reviewer:  Qiancheng Hu
Reviewer's report:
Recently, Citterio and co-workers have recently reviewed second line with oxaliplatin-
or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer (2018 Jul
3;9(51):29801-29809). First, I want to know why you did it again; in other words, what  do we
know and what do we not know? Second, exclusion criteria is not standardized, such as 'Also, we
excluded observational or phase I studies, reviews, letters, editorials, meeting abstracts, and case
reports'. Lastly,for any network meta-analysis, we would like to see more the quality evaluation
and data analysis of related  drug and non-drug interventions (2019; 367: l5460).
assistant